EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Disease‐specific neuropathological alterations of the locus coeruleus in Alzheimer's disease, Down syndrome, and Parkinson's disease

Marta Fructuoso, Yannick Vermeiren, Susana Boluda, Lev Stimmer, René A J Crans, Laura Xicota, Uli Eisel, Natalia Orti Casan, Philippe Bun, Charles Duyckaerts, Jean-Maurice Delabar, Andre Strydom und 4 weitere

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.70262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Marta Fructuoso und 15 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, CNRS, APHP, Hôpital de La Pitié-Salpêtrière, INSERM, Paris, France. Hauptthemen laut MEDLINE: Locus Coeruleus, Alzheimer Disease, Down Syndrome, Parkinson Disease. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Agence Nationale de la Recherche, Agencia Estatal de Investigación, MRC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION The locus coeruleus (LC), the brain's primary source of noradrenaline (NA), undergoes early neurodegeneration in Parkinson's disease (PD), Alzheimer's diseases (AD), and Down syndrome (DS); however, differences have not been examined in parallel. METHODS Post mortem brains ( n = 67) from individuals with AD, DS‐AD, and PD without and with dementia (PD‐D) and controls were analyzed for amyloid beta (Aβ), phosphorylated tau (pTau), α‐synuclein, endo‐lysosomal alterations, biogenic amines, and selective biomarkers. RESULTS LC degeneration correlated with age, peaking in AD and PD‐D, while NA and dopaminergic metabolites were significantly reduced only in PD‐D. DS‐AD, the youngest group, showed the highest Aβ and pTau levels but the least noradrenergic neuron loss. We demonstrated for the first time that endosomal alterations were present in AD, lysosomal changes were present in PD‐D/DS‐AD, and DYRK1A, a key protein from chromosome 21, was elevated only in DS‐AD. DISCUSSION Loss of noradrenergic neurons may occur independently of amyloid and tau pathologies. Highlights We provide the first analysis of neuropathological and biochemical features including biogenic amines of the LC in AD, DS, and PD. Loss of noradrenergic neurons was most severe in AD and PD. Only in DS, levels of DYRK1A – a kinase encoded on chromosome 21 and implicated in neurodegenerative processes – were elevated and negatively correlated to biogenic amine levels. Although individuals with DS having AD were the youngest group, they had the highest levels of amyloid and tau pathologies, but less noradrenergic neurons loss compared to other disease groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Locus CoeruleusAlzheimer DiseaseDown SyndromeParkinson DiseaseHumansMaleFemaleAgedAmyloid beta-Peptidestau ProteinsAged, 80 and overMiddle Agedalpha-SynucleinNorepinephrine

Stichwörter der Autor:innen

DYRK1Aendo‐lysosomal pathwaylocus coeruleusneurodegenerative diseases

Substanzen

Amyloid beta-Peptidestau Proteinsalpha-SynucleinNorepinephrine

Autor:innen und Institutionen

  • Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, CNRS, APHP, Hôpital de La Pitié-Salpêtrière, INSERM, Paris, France.
  • Laboratory of Neurochemistry and Behavior, Experimental Neurobiology Unit, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
  • Laboratoire de Neuropathologie R Escourolle, Hôpital de la Pitié-Salpêtrière, AP-HP, Paris, France.
  • Center for Genomic Regulation (CRG), The Barcelona Institute for Science and Technology, Carrer del Doctor Aiguader, Barcelona, Spain.
  • Department of Molecular Neurobiology, Groningen Institute of Evolutionary Life Science Faculty of Science and Engineering, University of Groningen, Groningen, The Netherlands.
  • Institute of Psychiatry and Neuroscience of Paris (IPNP), Université Paris Cité, INSERM U1266, NeurImag Core Facility, Paris, France.

Förderung

  • Agence Nationale de la Recherche
  • Agencia Estatal de Investigación
  • MRC
  • Spanish Ministry of Science and Innovation
  • Generalitat de Catalunya
  • Fondation Jérôme Lejeune, Fondation Sisley-d'Ornano
  • EMBL Partnership
  • Medical Research Council

Zitieren

APA

Fructuoso, M., Vermeiren, Y., Boluda, S., Stimmer, L., Crans, R. A. J., Xicota, L., Eisel, U., Casan, N. O., Bun, P., Duyckaerts, C., Delabar, J. M., Strydom, A., Van Dam, D., Dierssen, M., De Deyn, P., & Potier, M. C. (2025). Disease‐specific neuropathological alterations of the locus coeruleus in Alzheimer's disease, Down syndrome, and Parkinson's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70262

Vancouver

Fructuoso M, Vermeiren Y, Boluda S, Stimmer L, Crans RAJ, Xicota L, et al. Disease‐specific neuropathological alterations of the locus coeruleus in Alzheimer's disease, Down syndrome, and Parkinson's disease. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70262

BibTeX
@article{Fructuoso2025,
  author = {Fructuoso, Marta and Vermeiren, Yannick and Boluda, Susana and Stimmer, Lev and Crans, René A J and Xicota, Laura and Eisel, Uli and Casan, Natalia Orti and Bun, Philippe and Duyckaerts, Charles and Delabar, Jean-Maurice and Strydom, Andre and Van Dam, Debby and Dierssen, Mara and De Deyn, Peter and Potier, Marie-Claude},
  title = {Disease‐specific neuropathological alterations of the locus coeruleus in Alzheimer's disease, Down syndrome, and Parkinson's disease},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.70262}
}
Kostenlos starten →